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Purpose: Recent sequencing efforts have allowed for the 
molecular taxonomy of prostate cancer (TCGA, 2015). In a sub-
set of patients, mutations and copy-number losses in the 
homologous recombination pathway were found. The TONSL-
MMS22L complex has recently been shown to be involved in the 
recovery from replication stress through homologous 
recombination (Duro et al, 2010; O'Donnell et al, 2010). It 
physically associates with BRCA1/2, RAD51, and RPA. Our study 
sought to correlate TONSL complex expression with biochemical 
relapse in prostate cancer patients 
Methods and Materials: Our cohort consists of 250 patients with 
D’Amico-classified intermediate-risk prostate cancer, treated 
with image-guided radiotherapy (IGRT, n = 116) or radical 
prostatectomy (RadP, n = 134). Pre-treatment biopsies were 
analyzed using the Affymetrix Oncoscan array. The Phoenix and 
AUA criteria was used to define biochemical relapse for RadP and 
IGRT patients respectively. mRNA expression data was taken 
from the TCGA Provisional cohort using cBioPortal (Gao et al., 
2013). 
Results: Copy number alterations of TONSL and MMS22L were 
observed in 31% (n = 78) and 20% (n = 51) of our cohort 
respectively. They were predominantly gains in TONSL, but 
losses in MMS22L. TONSL amplification, but not MMS22L, was 
significantly associated with biochemical recurrence (Chi-square 
= 12, p < 0.001). TONSL remained significantly associated on 
multivariate analysis, controlling for tumour stage, Gleason 
score, and PSA (p < 0.005). In the TCGA cohort, over-expression 
of TONSL (p < 0.005) as well as other members of the homologous 
recombination pathway (e.g. RAD51D, BRCA1, XRCC2, POLD1, 
TOP3A, etc.) were associated with disease recurrence (p < 
0.001). 
Conclusions: We identified a novel association of copy-number 
gain and over-expression of TONSL with biochemical recurrence 
following radical prostatectomy or image-guided radiotherapy. 
This points to a potential gene dosage effect and the central role 
of the homologous recombination pathway in prostate cancer 
progression. 
 
228 
PATHOLOGIC AND TREATMENT FACTORS ASSOCIATED WITH 
RECURRENCE IN STAGE IA SEROUS ADENOCARCINOMA OF THE 
UTERUS  
Elysia Donovan, Lua Eiriksson, Clare Reade, Harkiran Kaur, 
Gregory Pond, Sadaf Memon, Laurie Elit, Iwa Kong 
McMaster University, Hamilton, ON 
 
Purpose: Serous adenocarcinoma is a rare aggressive histologic 
subtype of endometrial cancer with a high rate of recurrence and 
a poor prognosis even at early stages. The optimal approach to 
adjuvant treatment for early stage disease is unknown. Patients 
with endometrium limited disease and a complete 
lymphadenectomy are presumed to be at lower recurrence risk. 
We report on the pathologic and treatment characteristics of 
recurrent cases in a large cohort of serous endometrial cancer 
patients to investigate whether adjuvant therapy can be omitted 
in low-risk cases. 
Methods and Materials: A retrospective chart review inclusive of 
all cases of “serous carcinoma” of the endometrium from 2000-
2014 was completed. Patients with FIGO 2009 Stage IA pure or 
mixed serous histology who had undergone total hysterectomy 
and bilateral salpingo-oophorectomy were included. Kaplan-
Meier estimates were calculated for OS and RFS and hazard ratios 
for prognostic factors were calculated using Cox proportional 
hazards modeling. 
Results: There were 63 patients with FIGO Stage 1A disease. 
Median follow up was 30.2 months. Patients were observed (n = 
33) or received adjuvant treatment (chemotherapy plus 
brachytherapy n = 21; chemotherapy alone n = 7; or pelvic 
radiotherapy +/- chemotherapy n = 2). Fifty-seven patients 
(80.2%) had pelvic lymphadenectomy (median 9 nodes). Thirty-
two patients had endometrium-confined disease. There were 
seven recurrences (11.1%), at a median of 11 months (range 8-
35). At two and five years RFS was 89.3% and 85.8%; and OS was 
92.7% and 87.6%, respectively. Of those patients observed, four 
(12.1%) developed recurrence, with two vaginal recurrences 
only. In patients with endometrium-confined disease 9% 
developed recurrence, none of whom received adjuvant therapy. 
Two of 29 patients treated with chemotherapy as a component 
of their adjuvant treatment developed recurrence (6.9%). The 
majority of patients who recurred had extrapelvic recurrence 
with or without locoregional recurrence (71.4%). More than half 
of patients who recurred did not have adequate pelvic lymph 
node assessment (four of seven cases). On multivariate analysis 
only presence of myometrial invasion (HR 1.41, p = 0.63) and 
presence of lymphovascular invasion (HR 2.69, p = 0.29) were 
associated with inferior RFS, however these were not statistically 
significant. 
Discussion: In our cohort of early stage serous endometrial 
cancers RFS and OS were inferior to those reported for patients 
with endometriod histology. Our study indicates the importance 
of adequate surgical staging in early stage disease and supports 
the use of combination chemotherapy and brachytherapy in 
adjuvant treatment, even in patients with endometrium-
confined Stage 1A disease. 
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Purpose: Surgery and post-operative adjuvant chemotherapy are 
the mainstay of treatment for patients with Stage IIIC2 
endometrial cancer. The benefit of post-operative adjuvant 
radiotherapy (RT) is not as well defined. The purpose of this 
study was to compare the patterns of failure and survival in 
patients with Stage IIIC2 endometrial cancer, treated with or 
without post-operative RT, between two provinces where 
patterns of practice differ. 
Methods and Materials: Consecutive patients diagnosed with 
FIGO Stage IIIC2 endometrial cancer from 2000-2010 were 
identified through two provincial cancer registries. 
Clinicopathologic characteristics, treatment variables (adjuvant 
chemotherapy, radiation therapy), and outcomes (patterns of 
failure, disease-free survival (DFS) and overall survival (OS) were 
analyzed. Statistical analysis was performed on STATA 14. 
Results: Fifty patients with FIGO Stage IIIC2 endometrial cancer 
were identified. Twenty-three (46%) received adjuvant RT and 
27 (54%) did not receive any adjuvant RT (RT versus NRT). Ten 
received external beam RT (EBRT) to pelvic +/- para-aortic 
lymph nodes only; one received vaginal brachytherapy only; 11 
received both (one unknown). The median age at diagnosis was 
55 for the RT group and 69 for NRT group. Grade, histology, and 
depth of myometrial invasion were similar in both groups. The 
RT group received a median of three cycles of adjuvant 
chemotherapy, while the NRT group received six cycles. Twelve 
patients (52%) in the RT group and 21 patients (78%) in the NRT 
group had disease relapse. Distant and abdominal relapse rates 
were lower in the RT versus NRT groups, (30 versus 44%, and 26 
versus 48%, respectively); pelvic/vaginal relapses (17 versus 15%) 
were similar. Median DFS was better in RT group (26.7 versus 
12.5 months, p = 0.013), while median OS was not significantly 
different (32.5 versus 29.7 months, p = 0.26). Toxicities for the 
RT group consisted of Grade 1 and 2 gastrointestinal and 
genitourinary symptoms and fatigue; Grade 3 toxicities were 
uncommon. Further data collection to increase sample size is 
ongoing. 
Conclusions: Patients with Stage IIIC2 endometrial cancer who 
received adjuvant post-operative RT following three cycles of 
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chemotherapy had lower distant and abdominal relapse rates, 
and significantly better DFS versus those who received six cycles 
of chemotherapy and no adjuvant RT. Post-operative RT should 
be considered in the treatment regimen for this patient group.  
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Purpose: Most women with cervical cancer in Sub-Saharan Africa 
present with locally advanced disease. These women require 
external beam radiotherapy (EBRT) and brachytherapy for a 
curative treatment course. Data on the outcomes of these 
patients remain sparse. We report the experience of The 
National Centre for Radiotherapy and Nuclear Medicine in Accra, 
Ghana. 
Methods and Materials: The charts of patients treated from 
2006-2011 were reviewed. Patients treated without 
brachytherapy or with palliative intent were excluded. Staging 
CT scans were not routinely performed. Cobalt-60 EBRT was 
followed by one or two low-dose-rate brachytherapy insertions. 
Concurrent weekly cisplatin was recommended. Because many 
patients experienced delays from diagnosis to treatment, we 
calculated rates of locoregional recurrence (LRR), and distant 
recurrence (DR) from the date of the last radiation treatment to 
the event date, or last follow up, when no event recurred, using 
a competing risk approach. Overall survival was calculated from 
the date of diagnosis using the Kaplan-Meier method. 
Results: Two hundred and fifty-four patients had a median age 
at diagnosis of 55 years. FIGO stage was IB in 7% of patients, IIA 
in 13%, IIB in 43%, IIIA in 8%, IIIB in 25% (48% had sidewall 
involvement, 33% hydronephrosis, and 18% both), and IVA in 4%. 
Median dose to point A was 83 Gy (range 56-98 Gy) with a median 
contributing EBRT and brachytherapy dose of 46 Gy (range: 32-
52 Gy) and 29 Gy (range: 8-50 Gy), respectively. EBRT boosts to 
the sidewall or primary tumour were used in 12% of patients with 
a mean dose of 9 Gy (range: 4-20 Gy). Median doses to the ICRU 
bladder and rectal points were 71 Gy and 65 Gy. Sixty-four 
percent of patients received concurrent cisplatin. The median 
number of cycles was four, with 89% and 39% of patients 
receiving at least three and five cycles, respectively. Median 
overall treatment time was 73 days (range: 27-329 days). Median 
follow up was 2.5 years with many patients lost to follow up. 
Three-year OS, LRR, and DR were 87%, 20%, and 11%, 
respectively. The most commonly reported late side-effect was 
vaginal stenosis/shortening in 32% of patients. We also identified 
nearly 300 patients who were offered curative treatment but 
never returned to start; they will be the subjects of a subsequent 
study on barriers of care. 
Conclusions: We report the largest single institution series of 
cervical cancer patients treated with definitive EBRT and 
brachytherapy in Sub-Saharan Africa. Despite advanced stage at 
presentation, preliminary data is promising. However, many 
patients eligible for curative radiotherapy do not undergo 
treatment. 
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Background: Close resection margins (CM) and lymph node 
involvement with extracapsular extension (ECE) are associated 
with poor clinical outcome of patients with squamous cell head 
and neck cancer (SCCHNC) after surgical resection and adjuvant 
chemoradiation. We performed in this subset of patients an open 
label Phase 2 trial and investigated the effect of additional 
cetuximab administered concomitantly and as maintenance 
therapy during and after adjuvant radiochemotherapy. 
Methods and Materials: Surgically treated SCCHNC with CM or 
ECE were eligible for the study. 61.6 Gy (1.8/2.0/2.2 Gy, d1-36) 
were administered using an integrated boost IMRT-technique. 
Cisplatin (20 mg/m2, d1-5 and d29-33) and 5-FU (continuous 
infusion: 600 mg/m2, d1-d5 + d29-33) were given concurrently. 
Cetuximab started seven days prior to radiochemotherapy at 400 
mg/m2 followed by weekly doses of 250 mg/m2. Maintenance 
cetuximab began after radiochemotherapy at 500 mg/m² every 
two weeks for six months. The study was conducted at 10 
investigational sites recruiting in Germany from May 2008 until 
December 2010.  
Results: The number of patients enrolled was 83. Five patients 
did not meet inclusion criteria leaving 78 for analysis. Median 
follow up of was1.5 years. Eighteen patients had events (death 
of progression) of which 10 were locoregional relapses. Two-year 
overall survival, disease-free survival, and locoregional tumour 
control were 86% (95%CL 79-95%), 77% (95% CL 66-86%), and 82% 
(95%CL 93-78%). Acute toxicity was in the expected range 
(separate abstract). Two thirds of patients started maintenance 
cetuximab after completion of chemoradiation and on third 
completed all treatment as scheduled. 
Conclusions: Adjuvant radiochemotherapy with concomitant and 
maintenance cetuximab is feasible and results in a favourable 
clinical outcome in high-risk SCCHNC after surgical resection 
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Purpose: The causal relationship between cancer of the cervix 
uteri and infection with human papillomavirus (HPV) has been 
adequately studied. There are also indications that there is a link 
between HPV infection and squamous cell carcinoma of the head 
and neck. The aim of this study was to find out the incidence and 
clinical outcome of HPV infection in head neck cancer patients 
in a German population. 
Methods and Materials: In a retrospective study, the tumour 
tissue from 164 patients (110 men, 54 women, 62.8 years + 12.7) 
with head neck cancer (oropharynx = 65 nasopharynx = 10, larynx 
= 13, hypopharynx = 15, oral cavity = 33 CUP = five, Other = 23) 
were tested for HPV infection and the clinical outcome was 
investigated. p16 as a surrogate marker for HPV infection was 
determined. Moreover, risk factors such as nicotine, alcohol 
abuse, resection margin of the tumour tissue, histology, lymph 
nodes involvement, extracapsular spread, tumour stage, and the 
treatment of the tumour were analyzed for local control and 
overall survival. 
Results: The incidence of HPV infection in oropharynx-carcinoma 
patients was 33%. Patients with HPV-positive oropharyngeal 
carcinomas showed a tendency towards longer survival time, (p 
= 0.76, HR: 2.42, 95% CI 0.91 - 6.44) compared to HPV-negative 
tumours. All other parameters were except the tumour stage in 
the uni and multivariate analysis not significant for local control 
and overall survival. The reason for this might be the small 
number of cases in our individual subgroups 
